Idecabtagene vicleucel (ide-cel) is a novel CAR T-cell therapy that targets B-cell maturation antigen (BCMA), which is selectively expressed on mature B lymphocytes and has a relevant role for their survival and proliferation, explaining its value as a therapeutic target for R/R MM [3]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.